Trial Profile

BCMA-CD38 Bispecific Chimeric Antigen Receptor (CAR)-Modified T Cells in the Treatment of Relapsed or Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti BCMA anti CD38 bispecific chimeric antigen receptor T cell therapy Shengyan Pharmaceutical Technology (Primary)
Indications Multiple myeloma
Focus Adverse reactions; First in man

Most Recent Events

10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
07 Sep 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com